Hybio Pharmaceutical Co., Ltd. engages in the development, manufacture, and commercialization of therapeutic peptides API and peptide-based drugs in China and internationally. It offers liraglutide, semaglutide, and exenatide for diabetes; terlipressin, desmopressin, and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix, and atosiban for obstetrics and gynecology; customized peptides; working standards for the peptide APIs and related impurities; peptide CRO; and CDMO services, which include peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory, and dossier support. The company was founded in 1998 and is based in Wuhan, China.